Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Background and purpose Oligometastatic prostate cancer is a new and emerging treatment
field with only few prospective randomized studies published so far. Despite the lack of …

The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at
numerous phases of the disease and progress under intense evolutionary pressures. Organ …

Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …

Background Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is
very promising and has become a focus of current clinical research. Objective We …

Simple Summary Prostate Specific Membrane Antigen-Positron Emission Tomography
(PSMA-PET) is currently recommended to stage Prostate Cancer (PCa) patients with …

Background Biochemical recurrence (BCR) following primary interventional treatment
occurs in approximately one-third of patients with prostate cancer (PCa). Next-generation …

Purpose The role of metastasis-directed therapy (MDT) in molecularly defined oligorecurrent
prostate cancer (PCa) remains irresolute. We present extended follow-up and an …

Context Emerging evidence supports the use of stereotactic body radiation therapy (SBRT)
as metastatic-directed therapy (MDT) for oligometastatic genitourinary cancers; however, the …